RARE — Ultragenyx Pharmaceutical Share Price
0.000.00%
Last trade - 00:00- $3.54bn
- $3.06bn
- $560.23m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 23.34 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 5.7 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -50.34% | ||
| Return on Equity | -386.33% | ||
| Operating Margin | -86.94% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 271.03 | 351.41 | 363.33 | 434.25 | 560.23 | 651.85 | 839.21 | 40.12% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. Its four approved product candidates include Crysvita (burosumab) for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO), Mepsevii (vestronidase alfa) for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome, Dojolvi (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD), and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia (HoFH). Its clinical product candidates include DTX401, DTX301, UX701, UX143, UX111, and GTX-102. UX143 for the treatment of Osteogenesis Imperfecta.
Directors
- Daniel Welch NEC (63)
- Emil Kakkis PRE (60)
- Mardi Dier CFO (57)
- Karah Parschauer EVP (43)
- Camille Bedrosian EVP (68)
- Erik Harris EVP (51)
- Dennis Huang EVP (56)
- Thomas Kassberg EVP (60)
- John Pinion EVP (55)
- Corazon Sanders DRC (64)
- William Aliski IND (74)
- Deborah Dunsire IND (59)
- Lars Ekman IND (71)
- Matthew Fust IND (56)
- Michael Narachi IND (61)
- Shehnaaz Suliman IND (49)
- Last Annual
- December 31st, 2024
- Last Interim
- March 31st, 2025
- Incorporated
- June 13th, 2011
- Public Since
- January 31st, 2014
- No. of Shareholders
- 8
- No. of Employees
- 1,294
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 94,542,035
- Address
- 60 Leveroni Ct, NOVATO, 94949-5746
- Web
- https://www.ultragenyx.com/
- Phone
- +1 4154838800
- Auditors
- Ernst & Young LLP
Upcoming Events for RARE
Q2 2025 Ultragenyx Pharmaceutical Inc Earnings Release
Q3 2025 Ultragenyx Pharmaceutical Inc Earnings Release
Similar to RARE
Alnylam Pharmaceuticals
NASDAQ Global Select Market
Amgen
NASDAQ Global Select Market
Amneal Pharmaceuticals
NASDAQ Global Select Market
Amphastar Pharmaceuticals
NASDAQ Global Select Market
Apellis Pharmaceuticals
NASDAQ Global Select Market
FAQ
What is the Ultragenyx Pharmaceutical share price?
As of Today at 11:51 UTC, shares in Ultragenyx Pharmaceutical are trading at $35.61. This share price information is delayed by 15 minutes.
How has the Ultragenyx Pharmaceutical share price performed this year?
Shares in Ultragenyx Pharmaceutical last closed at $35.61 and the price had moved by -16.43% over the past 365 days. In terms of relative price strength the Ultragenyx Pharmaceutical share price has underperformed the S&P500 Index by -25.62% over the past year.
What are the analyst and broker recommendations for Ultragenyx Pharmaceutical?
The overall consensus recommendation for Ultragenyx Pharmaceutical is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Ultragenyx Pharmaceutical dividend yield?
Ultragenyx Pharmaceutical does not currently pay a dividend.
Does Ultragenyx Pharmaceutical pay a dividend?
Ultragenyx Pharmaceutical does not currently pay a dividend.
When does Ultragenyx Pharmaceutical next pay dividends?
Ultragenyx Pharmaceutical does not currently pay a dividend.
How do I buy Ultragenyx Pharmaceutical shares?
To buy shares in Ultragenyx Pharmaceutical you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Ultragenyx Pharmaceutical?
As of the previous close price of $35.61, shares in Ultragenyx Pharmaceutical had a market capitalisation of $3.37bn.
Where are Ultragenyx Pharmaceutical shares listed?
Here are the trading details for Ultragenyx Pharmaceutical:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: RARE
What kind of share is Ultragenyx Pharmaceutical?
Based on an overall assessment of its quality, value and momentum Ultragenyx Pharmaceutical is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Ultragenyx Pharmaceutical share price forecast for 2025?
The analyst consensus target price for shares in Ultragenyx Pharmaceutical is $89.39. That is 151.02% above the last closing price of $35.61.
Analysts covering Ultragenyx Pharmaceutical currently have a consensus Earnings Per Share (EPS) forecast of -$5.31 for the next financial year.
Find out moreWhat is the trend in the Ultragenyx Pharmaceutical share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Ultragenyx Pharmaceutical. Over the past six months, its share price has underperformed the S&P500 Index by -21.29%.
As of the last closing price of $35.61, shares in Ultragenyx Pharmaceutical were trading -22.54% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Ultragenyx Pharmaceutical PE Ratio?
The Ultragenyx Pharmaceutical PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $35.61.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Ultragenyx Pharmaceutical?
Ultragenyx Pharmaceutical's management team is headed by:
- Daniel Welch - NEC
- Emil Kakkis - PRE
- Mardi Dier - CFO
- Karah Parschauer - EVP
- Camille Bedrosian - EVP
- Erik Harris - EVP
- Dennis Huang - EVP
- Thomas Kassberg - EVP
- John Pinion - EVP
- Corazon Sanders - DRC
- William Aliski - IND
- Deborah Dunsire - IND
- Lars Ekman - IND
- Matthew Fust - IND
- Michael Narachi - IND
- Shehnaaz Suliman - IND